A5017767151- Renal Transplantation Outcomes and Treatments
- Complement system in diseases
- Organ Donation and Transplantation
- Transplantation: Methods and Outcomes
- Renal Diseases and Glomerulopathies
- Polyomavirus and related diseases
- Organ Transplantation Techniques and Outcomes
- Renal and Vascular Pathologies
- Dialysis and Renal Disease Management
- COVID-19 Clinical Research Studies
- Viral-associated cancers and disorders
- Pregnancy and Medication Impact
- Adenosine and Purinergic Signaling
- Lysosomal Storage Disorders Research
- Vascular Malformations and Hemangiomas
- Chronic Kidney Disease and Diabetes
- Blood Pressure and Hypertension Studies
- Cytomegalovirus and herpesvirus research
- Iron Metabolism and Disorders
- Neurological Complications and Syndromes
- Parvovirus B19 Infection Studies
- Cardiovascular Function and Risk Factors
- SARS-CoV-2 and COVID-19 Research
- Lymphatic Disorders and Treatments
- Vaccine Coverage and Hesitancy
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
2005-2022
University of Insubria
2021
University of Milano-Bicocca
2020
Ospedale Maggiore
2005-2019
Azienda Ospedaliero-Universitaria Careggi
2013-2018
University of Florence
2014-2018
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
2005
Atypical hemolytic uremic syndrome (aHUS) is a rare genetic life-threatening disease of chronic uncontrolled complement activation leading to thrombotic microangiopathy (TMA) and severe end-organ damage. Eculizumab, terminal inhibitor approved for aHUS treatment, was reported improve hematologic renal parameters in 2 prior prospective phase studies. This the largest study eculizumab date, conducted an adult population.Open-label single-arm trial.Patients 18 years or older with (platelet...
There are limited long-term outcome data in eculizumab-treated patients with atypical hemolytic uremic syndrome (aHUS). We report final results from the largest prospective, observational, multicenter study of aHUS treated eculizumab.Patients who participated any five parent eculizumab trials and received at least one infusion were eligible for enrollment a follow-up study. Rates thrombotic microangiopathy (TMA) manifestations off versus on evaluated. Additional endpoints included change...
Abstract Background There are limited published data concerning the effects of different immunosuppressive regimens on development polyomavirus ( BKV ) viremia. We examined risk developing viremia in kidney transplant recipients receiving everolimus EVR or mycophenolic acid MPA as maintenance therapy. Methods observationally analyzed 296 patients who underwent renal transplantation at our center between 2005 and 2010: 58 were treated with low‐dose cyclosporine (LD‐CyA) (group 1) 238...
Interferon-beta (IFN-beta) is one of the most widely prescribed medications for relapsing-remitting multiple sclerosis (RRMS). IFN-related thrombotic microangiopathy (TMA) a rare but severe complication, with fulminant clinical onset and possibly life-threatening outcome that may occur years after well-tolerated treatment IFN. Most patients evolve rapidly to advanced chronic kidney disease eventually renal failure.
A follow-up study of 1844 renal transplant patients in Italy showed a 113-fold increased risk for Kaposi's sarcoma. sarcoma was higher persons born southern than northern Italy. Significant increases were also observed cancers the lip, liver, kidney and non-Hodgkin's lymphoma.
Eculizumab, a terminal complement inhibitor, is approved for atypical haemolytic uraemic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA).In five parent studies, eculizumab effectively prevented TMA and improved renal haematologic outcomes in patients with aHUS; therefore, these could enrol this long-term, prospective, observational multicentre study. The primary endpoint was the manifestation rate off on post-parent Post hoc analyses evaluated rates during...
The reliability of kidney biopsy as the sole means for assessing kidneys from extended-criteria donors (ECDs) to be allocated single or dual transplantation is still a matter debate. We compared retrospectively 3 years graft survival and renal function in 44 recipients marginal donor with good Karpinski histological score ≤3 56 transplant 4 5. donors' recipients' characteristics were by Wilcoxon's rank-sum test Fisher's exact test, was analysed using log-rank Cox regression analysis. worse...
Abstract The quality of follow-up has clearly emerged as a key factor for long-term kidney graft survival. Currently, many clinics are facing difficulties in delivering optimal surveillance because the increased number and complexity transplant recipients, COVID-19 pandemic. Additional ways performing visits needed telemedicine tool to strengthen patient care intensity. Six Italian surgeons nephrologists convened via teleconference develop consensual model video recipients. Issues discussed...
Observation that 1,25-Dihydroxyvitamin-D3 has an immunomodulatory effect on innate and adaptive immunity raises the possible clinical graft outcome. Aim of this study was to evaluate correlation biopsy-proven acute rejection, CMV infection, BKV with deficiency benefit calcitriol supplementation before during transplantation. Risk factors kidney function were also evaluated. All RTRs received induction therapy basiliximab, cyclosporine, mycophenolic acid, steroids. During first year,...
Familial hypertension, glomerular hemodynamic alterations, and dysregulation of tubulo-glomerular feedback (TGFB) have all been associated with the development chronic renal failure. In present study we evaluated hemodynamics TGFB responses in healthy kidney donors either or without familial before after nephrectomy.
Transplant renal artery stenosis (TRAS) is the most frequent vascular complication after kidney transplantation (KT) and has been associated with potentially reversible refractory hypertension, graft dysfunction, reduced patient survival. The aim of study to describe outcomes a standardized Duplex Ultrasound- (DU-) based screening protocol for early diagnosis TRAS selection patients requiring endovascular intervention. We retrospectively reviewed our prospectively collected database KT from...
Background We compared protection of mycophenolate mofetil (MMF) and azathioprine (AZA) against acute cellular rejection (ACR) chronic allograft nephropathy (CAN) in kidney transplant recipients on steroid-free, low-dose cyclosporine (CsA) microemulsion maintenance immunosuppression. Methods findings ATHENA, a pragmatic, prospective, multicenter trial conducted by 6 Italian centers, the outcomes 233 consenting first deceased donor induced with thymoglobulin basiliximab randomized to MMF (750...